CNTB Stock Summary and Trading Ideas (Connect Biopharma Hldgs | NASDAQ:CNTB)

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Connect Biopharma Hldgs trades on the NASDAQ stock market under the symbol CNTB.

As of April 27, 2026, CNTB stock price declined to $2.45 with 140,236 million shares trading.

CNTB has a beta of -1.98, meaning it tends to be less sensitive to market movements. CNTB has a correlation of 0.09 to the broad based SPY ETF.

CNTB has a market cap of $136.96 million. This is considered a Micro Cap stock.

Last quarter Connect Biopharma Hldgs reported $0 in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-20,630 and exceeded earnings estimates by $.03.

In the last 3 years, CNTB traded as high as $3.82 and as low as $.51.

CNTB has outperformed the market in the last year with a return of +216.7%, while the SPY ETF gained +32.2%. However, in the most recent history, CNTB shares have underperformed the stock market with its stock returning -3.5% in the last 3 month period and -13.1% for the last 2 week period, while SPY has returned +4.0% and +5.3%, respectively.

CNTB support price is $2.37 and resistance is $2.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTB shares will trade within this expected range on the day.